

Monthly Market Commentary

Global equity markets continued performing well through October, supported by easing US-China trade tensions, lower rates, a good reporting season, and more AI euphoria. Against this backdrop, large-cap growth outperformed alongside a deterioration in breadth.

Japan's Nikkei225 was the standout performer amongst developed indices, rising 16.6%, as investors cheered a falling JPY (helps exports) and the promotion of Sanae Takaichi to PM. As a supporter of 'Abenomics', markets are anticipating a renewed period of ultra-easy monetary policy, aggressive fiscal stimulus, and more structural reforms.

US large caps also performed strongly, with the NASDAQ and S&P500 up 4.7% and 2.27%, respectively. Both brushed aside credit wobbles, some hawkish Fed language, and a US government shutdown, to reach new record highs. While angst over rising AI costs weighed on Meta's stock, investors remained broadly supportive of the AI complex following a spate of deal-making, with the bulk of index gains attributed to tech-stocks.

However, performance outside of tech was more mixed with the S&P500 Equal-Weighted Index falling 1% in October. Pockets of weakness included consumer exposed stocks, most notably restaurant operator, Chipotle. Its stock fell 18% after issuing poor Q4 guidance on the back of lower foot-traffic and input cost pressure. Other examples of weakness included distributor, Fastenal – a good proxy for the industrial cycle – where management flagged pricing pressures. Small caps, more sensitive to macro conditions, were also lower with the S&P600 Small Cap Index down 0.9% in October.

In Europe, most bourses delivered good performance in local currency terms. The UK FTSE rose 3.9% thanks to outsized exposure to higher commodity prices with France's CAC40 also up 2.9%, despite ongoing political dramas. Germany's DAX lagged, rising only 0.3% (down 1.6% in USD terms), while China's Shanghai Composite Index closed up 1.9%.

On a sector basis, performance was led by Information Technology, up 6.5%. Other sectors that did well included Utilities and Health Care, up 2.9% and 3%, respectively. Exposure to private credit woes weighed on Financial Services, which fell 2.1%. Ongoing weakness in chemicals and packaging contributed to Materials falling -2.8%, with oil price weakness also seeing Energy decline by 0.5%.

Against this backdrop the Fund returned -0.45% for the month.

The AUD fell 1% against the USD while commodities were broadly stronger with the Bloomberg Commodity Index up 2.6%, despite a 2.2% fall in WTI Oil prices. The VIX rose 1.16 points to close at 17.44 along while yields on US 10yr Treasuries fell 7bps to 4.08%.

The Fund's holdings in US goldminer Newmont and Swiss-based Nestle, were the two biggest contributors to performance in October. Given Newmont trades on a ~9% FCF yield (at current spot prices) with no balance sheet risk, it remains a material holding for the Fund. We took advantage of the strength in Nestle's stock following a well-received Q3 result to exit on valuation grounds.

Recruitment firm Robert Half, catering group Sodexo, and US-based reinsurer Everest Group were the top three detractors to performance in October, all de-rating on underwhelming results. In the case of Everest, a disappointing Q3 result and news that it was selling the retail insurance business (~15% of the group premiums and the source of Q3 weakness), saw its stock fall ~11%. However, retail was at best a break-even operation, with the rest of the business generating low-to-mid teens ROE that continues to trade well. Hence, with the stock now trading at ~0.76x FY26e Book Value, alongside ongoing buybacks, we think the shares offer an excellent skew for shareholders and have added to the position. We also continue to hold Robert Half and Sodexo on valuation grounds.

We believe the most compelling way to compound clients' wealth is by utilising multiple return sources to deliver superior risk-adjusted investment outcomes.

- Long-term compounding of investor wealth
- Multiple sources of return
- Quarterly distributions
- Risk focused investment mindset



The investment process behind the Talaria Global Equity Fund Complex ETF takes a high conviction, value biased approach to construct a portfolio of high quality, large cap companies from around the globe. Our unique investment methodology harnesses the benefits of consistent income generation and capital appreciation to grow investors' real wealth.

Performance as at 31 October 2025¹

	1 Month	3 Months	6 Months	1 Year	3 Years (pa)	5 Years (pa)	7 Years (pa)	10 Years (pa)	Since Inception (pa) ²
Total Return	-0.45%	1.28%	1.64%	5.52%	8.62%	11.29%	8.36%	7.24%	7.33%
Avg. Market Exposure ⁴	60%	59%	59%	63%	60%	58%	58%	59%	61%

¹ Fund Returns are calculated after fees and expenses and assume the reinvestment of distributions.
² Inception date for performance calculation is 18 August 2008.
³ Past performance is not a reliable indicator of future performance.


⁴ Average Market Exposure calculated on delta-adjusted exposure of underlying portfolio. Since inception market exposure is calculated from September 2008.

Growth of \$10,000 Since Inception⁵



⁵ Calculations are based on exit price, net of management fees and expenses and assumes reinvestment of distributions Past performance is not a reliable indicator of future performance.

Annual Distributions⁶




⁶ Illustrates Distribution Returns for the Talaria Global Equity Fund Complex ETF Units for the financial year ending 30 June 2025. Inception date is 18 August 2008.

Top 10 Holdings⁷

Company Name	Holding	Country	Sector	Description
Newmont	6.0%	USA	Materials	One of the top 3 gold producers in the world
Roche	4.4%	Switzerland	Health Care	A global leader in cancer treatments
Johnson & Johnson	4.3%	USA	Health Care	Pharmaceutical, medical devices and consumer health products company
EOG Resources	4.3%	USA	Energy	One of North America’s largest independent oil and gas producers
Everest Re	4.2%	USA	Financials	Leading global provider of reinsurance and insurance services
CF Industries	4.1%	USA	Materials	North America’s largest manufacturer of nitrogen-based fertiliser
Bunzl	3.9%	United Kingdom	Industrials	Multinational distribution and outsourcing business
Chubb	3.9%	USA	Financials	Global property and casualty insurance company
Pfizer	3.8%	USA	Health Care	A research led global pharmaceutical company
Essity	3.7%	Sweden	Consumer Staples	A global health and hygiene company based in Sweden


7 Weightings include option positions held and cash backing put options. It assumes that put options will be exercised. Should the put option not be exercised the cash will revert to the unencumbered cash portfolio or may be used to cover further put options.

Sector Allocation⁸



8,9 Weightings include option positions held and cash backing put options It assumes that put options will be exercised. Should the put option not be exercised the cash will revert to the unencumbered cash portfolio or may be used to cover further put options.

Regional Allocation⁹



* USA includes American Depositary Receipts (ADRs) listings.

Fund Snapshot

APIR Code	AUS0035AU	Inception Date	18 August 2008
Management Fee	1.16% p.a. of the net asset value of the Fund plus Recoverable Expenses	Liquidity	Daily
Recoverable Expenses	Estimated to be 0.12% of net asset value of the Fund each Financial Year	Exit Price	\$4.8304 (31 Oct 2025)
Major Platform Availability	Asgard, Ausmaq, BT Panorama, BT Wrap, CFS Edge, CFS FirstChoice, Dash, Expand, Hub24, IconiQ, IOOF Pursuit, Linear, Macquarie, Mason Stevens, Netwealth, North, Powerwrap, Praemium	Buy / Sell Spread	0.20% / 0.20%
		Distributions	Quarterly
		Minimum Investment	\$5,000

Important Information

Equity Trustees Limited ("Equity Trustees") (ABN 46 004 031 298), AFSL 240975, is the Responsible Entity for the Talaria Global Equity Fund Complex ETF ("the Fund"). Equity Trustees is a subsidiary of EQT Holdings Limited (ABN 22 607 797 615), a publicly listed company on the Australian Securities Exchange (ASX: EQT). This report has been prepared by Talaria Asset Management (Talaria) to provide you with general information only. In preparing this information, we did not take into account the investment objectives, financial situation or particular needs of any particular person. It is not intended to take the place of professional advice and you should not take action on specific issues in reliance on this information. Neither Talaria, Equity Trustees nor any of its related parties, their employees or directors, provide any warranty of accuracy or reliability in relation to such information or accepts any liability to any person who relies on it. Past performance should not be taken as an indicator of future performance. You should obtain a copy of the Product Disclosure Statement before making a decision about whether to invest in this product. Talaria Global Equity Fund Complex ETF's Target Market Determination is available [here](#). A Target Market Determination is a document which is required to be made available from 5 October 2021. It describes who this financial product is likely to be appropriate for (i.e. the target market), and any conditions around how the product can be distributed to investors. It also describes the events or circumstances where the Target Market Determination for this financial product may need to be reviewed. The Zenith Investment Partners (ABN 27 103 132 672, AFS Licence 226872) ("Zenith") rating (assigned November 2024 for fund AUS0035AU) referred to in this piece is limited to "General Advice" (s766B Corporations Act 2007) for Wholesale clients only. This advice has been prepared without taking into account the objectives, financial situation or needs of any individual, including target markets of financial products, where applicable, and is subject to change at any time without prior notice. It is not a specific recommendation to purchase, sell or hold the relevant product(s). Investors should seek independent financial advice before making an investment decision and should consider the appropriateness of this advice in light of their own objectives, financial situation and needs. Investors should obtain a copy of, and consider the PDS or offer document before making any decision and refer to the full Zenith Product Assessment available on the Zenith website. Past performance is not an indication of future performance. Zenith usually charges the product issuer, fund manager or related party to conduct Product Assessments. Full details regarding Zenith's methodology, ratings definitions and regulatory compliance are available on our Product Assessments and at Fund Research Regulatory Guidelines. The rating issued 04/2025 is published by Lonsec Research Pty Ltd ABN 11 151 658 561 AFSL 421 445 (Lonsec). Ratings are general advice only, and have been prepared without taking account of your objectives, financial situation or needs. Consider your personal circumstances, read the product disclosure statement and seek independent financial advice before investing. The rating is not a recommendation to purchase, sell or hold any product. Past performance information is not indicative of future performance. Ratings are subject to change without notice and Lonsec assumes no obligation to update. Lonsec uses objective criteria and receives a fee from the Fund Manager. Visit [lonsec.com.au](#) for ratings information and to access the full report. © 2025 Lonsec. All rights reserved. The Genium rating (assigned May 2025) presented in this document is issued by Genium Investment Partners Pty Ltd ABN 15 165 099 785, which is a Corporate Authorised Representative of Genium Advisory Services Pty Ltd ABN 94 304 403 582, AFSL 246580. The Rating is limited to "General Advice" (s766B Corporations Act 2007 (Cth)) and has been prepared without taking into account the objectives, financial situation or needs of any individual, including target markets of financial products, where applicable, and is subject to change at any time without notice. Past performance information is for illustrative purposes only and is not indicative of future performance. It is not a recommendation to purchase, sell or hold the relevant product(s). Investors should seek independent financial advice before making an investment decision in relation to this financial product(s). Genium receives a fee from the Fund Manager for researching and rating the product(s). Visit [Genium.com.au](#) for information regarding Genium's Ratings methodology. The Global Industry Classification Standard ("GICS") was developed by and is the exclusive property and a service mark of MSCI Inc. ("MSCI") and Standard & Poor's, a division of The McGraw-Hill Companies, Inc. ("S&P") and is licensed for use by Talaria Asset Management. Neither MSCI, S&P nor any third party involved in making or compiling the GICS or any GICS classifications makes any express or implied warranties or representations with respect to such standard or classification (or the results to be obtained by the use thereof), and all such parties hereby expressly disclaim all warranties of originality, accuracy, completeness, merchantability and fitness for a particular purpose with respect to any of such standard or classification. Without limiting any of the foregoing, in no event shall MSCI, S&P, any of their affiliates or any third party involved in making or compiling the GICS or any GICS classifications have any liability for any direct, indirect, special, punitive, consequential or any other damages (including lost profits) even if notified of the possibility of such damages.

